ArticleJournal of clinical microbiology2006
Rapid susceptibility testing of medically important zygomycetes by XTT assay.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Haematologica · 2013Guideline
- A Case Report of Acute Lymphoblastic Leukemia Complicated by Naso-Ophthalmic Mucormycosis.Cureus · 2025Article
- Unveiling the antifungal mechanisms of CTP, a new copper(II)-theophylline/1,10-phenanthroline complex, on drug-resistant non-albicans Candida species.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates.The Journal of antimicrobial chemotherapy · 2022Article
- Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms ofAntimicrobial agents and chemotherapy · 2021Article
- Efficiency of Candida tropicalis for Potential Degradation of Metalaxyl in the Aqueous Media.Current microbiology · 2020Article
- Isolation and molecular identification of Aspergillus flavus and the study of its potential for malathion biodegradation in water.World journal of microbiology & biotechnology · 2020Article
- The role of Rhodotorula mucilaginosa in selected biological process of wild fish.Fish physiology and biochemistry · 2019Article
- Pseudomonas aeruginosa Inhibits the Growth of Scedosporium and Lomentospora In Vitro.Mycopathologia · 2018Article
- CotH3 mediates fungal invasion of host cells during mucormycosis.The Journal of clinical investigation · 2014Article
- An antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosis.PloS one · 2013Article
- Rhino-orbital-cerebral mucormycosis.Current infectious disease reports · 2012Article
- Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.Journal of clinical microbiology · 2010Article
- Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence.Infection and immunity · 2010Article
- Potential antifungal effects of human platelets against zygomycetes in vitro.The Journal of infectious diseases · 2009Article
- Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes.Journal of clinical microbiology · 2008Article
- Mucormycosis in immunochallenged patients.Journal of emergencies, trauma, and shock · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The XTT colorimetric assay quantifies fungal growth by measuring fungal metabolism and has been used successfully for susceptibility testing of Aspergillus species after 24 and 48 h of incubation. In the present study using 14 clinical isolates of Zygomycetes (Rhizopus oryzae [5 isolates], Cunninghamella spp. [3 isolates], Mucor spp. [3 isolates], and Absidia corymbifera [3 isolates]), significant metabolic activity was demonstrated before visual or spectrophotometric detection of fungal growth by performing the XTT assay as early as 6 h after inoculation. Testing of susceptibility to amphotericin B, posaconazole, and voriconazole was subsequently performed using the XTT method (100 microg/ml XTT, 25 microM menadione) at 6, 8, or 12 h after inoculation and the CLSI (formerly NCCLS) M38-A method with visual and spectrophotometric MIC determinations at 24 h after inoculation. Concentration-effect curves obtained with the use of the E(max) model (a sigmoid curve with variable slope) were comparable between the early XTT and spectrophotometric readings at 24 h. Complete inhibition of early metabolic activity with the azoles was delayed in comparison to that with amphotericin B. Using appropriate cutoff levels, agreement was demonstrated between the early XTT and 24-h spectrophotometric or visual readings. In particular, for MIC-0 (the lowest drug concentration showing absence of visual growth) of amphotericin B, overall agreement levels were 90 to 93% for the 6-h XTT assay and 100% for the 8- and 12-h time points. For MIC-0 of posaconazole, agreement levels were 86% for the 6-h XTT and 93 to 100% for the 8- and 12-h time points. The overall agreement levels for MIC-0 and MIC-2 (the lowest drug concentration showing prominent reduction of growth compared with the control well) of voriconazole (compared with 24-h spectrophotometric readings) were 93 to 98% for the 8- and 12-h XTT assays. These results support the use of the XTT method for rapid MIC determination for Zygomycetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.